Mechanism of B-Cerebral Amyloidosis
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2000 - February 28, 2002
Grant ID
A2000044
Summary
Although there have been many efforts to understand the molecular and cellular details of b amyloid production, there is little information on the larger anatomical level. It is unclear how amyloid forms into plaques, how it appears in vessels, and whether cerebral amyloid results in neurodegeneration. Dr. Jucker is using APP transgenic mice to study cerebral amyloidosis and neuron loss. He is transplanting transgenic brain tissue into the brains of normal mice to determine whether amyloid deposits begin at specific anatomical sites such as the synapses, and whether vascular amyloid accumulates only at the site of the graft or throughout the entire brain. These experiments may also help to determine why some brain regions are more likely to develop amyloid deposits, the effect of aging on amyloid deposition, and whether amyloid deposited by the graft may be toxic to host neurons.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD